Keiichiro Kushiro
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$11.1MFederal grants as PI17 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
17 awards · $11.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ring | $1.2M | MUCOMMUNE, LLC |
| Sep 4, 2026 | NIH | SBIR Phase II Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception | $1.2M | MUCOMMUNE, LLC |
| Aug 5, 2026 | NIH | SBIR Phase I Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis | $309K | MUCOMMUNE, LLC |
| May 26, 2026 | NIH | SBIR Phase II IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | $993K | MUCOMMUNE, LLC |
| Sep 17, 2025 | NIH | SBIR Phase I Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia | $410K | MUCOMMUNE, LLC |
| Sep 12, 2025 | NIH | SBIR Phase II Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception | $1.1M | MUCOMMUNE, LLC |
| Sep 8, 2025 | NIH | SBIR Phase I Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity | $360K | MUCOMMUNE, LLC |
| Aug 21, 2025 | NIH | SBIR Phase I Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis | $310K | MUCOMMUNE, LLC |
| Jun 23, 2025 | NIH | SBIR Phase II IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | $1.0M | MUCOMMUNE, LLC |
| Dec 20, 2024 | NIH | SBIR Phase I IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | $291K | MUCOMMUNE, LLC |
| Jan 22, 2024 | NIH | SBIR Phase I IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | $291K | MUCOMMUNE, LLC |
| Mar 30, 2023 | NIH | SBIR Phase I Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis | $306K | MUCOMMUNE, LLC |
| Sep 1, 2022 | NIH | SBIR Phase I User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring | $259K | MUCOMMUNE, LLC |
| Aug 29, 2022 | NIH | SBIR Phase I Fast dissolving antibody tablets for preventing vaginal HSV transmission | $307K | MUCOMMUNE, LLC |
| Jun 30, 2022 | NIH | SBIR Phase I Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody | $278K | MUCOMMUNE, LLC |
| Apr 8, 2022 | NIH | SBIR Phase II Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $791K | MUCOMMUNE, LLC |
| Apr 1, 2021 | NIH | SBIR Phase II Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $1.7M | MUCOMMUNE, LLC |
Peer ranks
Federal funding#51
Awards as PI#29
Patents#273
Companies
- MUCOMMUNE, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.